首页> 外文会议>International Conference on Biomedical Engineering and Informatics >Interphase FISH of Chromosome 1 And 13 in Newly Diagnosed Myeloma and the Disease Prognosis
【24h】

Interphase FISH of Chromosome 1 And 13 in Newly Diagnosed Myeloma and the Disease Prognosis

机译:新诊断术骨髓瘤和疾病预后的染色体1和13的差异

获取原文

摘要

Due to the heterogeneity of the myeloma genomes, it is unlikely to remedy the disease with a standard therapeutic protocol. In principle, all therapies are considered palliative. To achieve the best clinical outcomes, the therapeutic protocols were implemented with high-dose chemotherapies followed by autologous hematopoietic stem cell transplantation as the standard treatments for newly diagnosed myeloma cases. In parallel with the clinical protocols, bone marrow specimens were collected at the diagnosis stage of more than 500 patients. The assessment of the prognostic and predictive impact of cytogenetic anomalies in the tumor cells was carried out using fluorescent in situ hybridization (FISH) procedure to probe chromosome lq21, lp13, 13q14, and 13q34 regions. The cytogenetic aberrations in myeloma cells are corroborated with clinical observation for the prognostic significance. The current study revealed that the amplification of lq21 and deletion of 1p13 chromosome regions are the significant risk factors when considering overall survival and event-free survival of the patients.
机译:由于骨髓瘤基因组的异质性,不太可能用标准治疗方案弥补疾病。原则上,所有疗法都被认为是姑息性的。为了达到最佳临床结果,治疗方案用高剂量化疗实施,然后进行自体造血干细胞移植作为新诊断的骨髓瘤病例的标准处理。与临床方案平行,在500多名患者的诊断阶段收集骨髓标本。使用荧光原位杂交(鱼)方法对肿瘤细胞中细胞遗传学异常对肿瘤细胞中的预测和预测性的评估进行探针染色体LQ21,LP13,13,13,13Q4区。骨髓瘤细胞中的细胞遗传学畸变被证实,临床观察对于预后意义。目前的研究表明,LQ21的扩增和1P13染色体区域的缺失是在考虑患者的整体存活和无事假时的显着风险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号